Takeda Pharmaceutical Co Ltd (TKPYY.PK)

TKPYY.PK on OTC Markets Group

20.98USD
23 Oct 2014
Price Change (% chg)

-- (--)
Prev Close
$20.98
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
34,627
52-wk High
$25.09
52-wk Low
$20.47

TKPYY.PK

Chart for TKPYY.PK

About

Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Company operates in three business segments. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer... (more)
No analyst recommendations are available for TKPYY.PK.

Overall

No Ratios Available.

Financials

  TKPYY.PK Industry Sector
P/E (TTM): -- 33.08 33.86
EPS (TTM): -- -- --
ROI: -- 18.26 17.53
ROE: -- 18.93 18.34
Search Stocks

BUZZ-Orexigen Therapeutics Inc: Diet drug launched

** Drugmaker's shares up 20 pct at $4.88, biggest intra-day percentage jump in more than two years

21 Oct 2014

Seattle Genetics and Takeda's cancer drug meets main trial goal

- Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer.

29 Sep 2014

UPDATE 1-Seattle Genetics and Takeda's cancer drug meets main trial goal

Sept 29 - Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer.

29 Sep 2014

Seattle Genetics, Takeda's cancer drug meets main goal in trial

Sept 29 - Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer.

29 Sep 2014

CORRECTED-UPDATE 1-Takeda, Lilly lose bid to overturn $9 bln award for hiding cancer risk

(Corrects number of decisions in Actos lawsuits from three to six in final paragraph)

30 Aug 2014

Takeda, Lilly lose bid to overturn $9 billion award for hiding cancer risk

- Takeda Pharmaceutical Co Ltd and Eli Lilly & Co lost a bid to overturn a combined $9 billion punitive damage award by a U.S. jury for hiding cancer risks associated with their Actos diabetes drug, according to a court ruling.

29 Aug 2014

UPDATE 1-Takeda, Lilly lose bid to overturn $9 bln award for hiding cancer risk

* Takeda shares muted, up 0.4 pct (Adds Takeda comment, Actos study result, share price, other details)

29 Aug 2014

Takeda, Lilly lose bid to overturn $9 bln award for hiding cancer risk

Aug 28 - Takeda Pharmaceuticals and Eli Lilly & Co lost a bid to overthrow a combined $9 billion punitive-damage award by a U.S. jury for hiding cancer risks associated with their Actos diabetes drug, according to a court ruling.

28 Aug 2014

Japanese drugmaker Takeda to raise the bar on research projects

TOKYO - Japan's biggest drugmaker Takeda Pharmaceutical Co will become more selective in its choice of research and development projects, its newly appointed president said on Tuesday, as the company struggles with shrinking margins due to a dearth of new blockbuster products.

05 Aug 2014

UPDATE 1-Drug maker Orion's Q2 profit rises on Bayer, Takeda payments

* Result boosted by one-off payments from Bayer and Takeda

29 Jul 2014

Earnings vs. Estimates

No consensus analysis data available.

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks